NEW YORK, Sept 30 — Zogenix Inc said yesterday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.

The drug was being compared with a placebo in children having Dravet syndrome, a genetic dysfunction in the brain that leads to potentially fatal, long-lasting, fever-related seizures that do not respond to standard treatment. — Reuters